Dashboard/CONCORDBIO

CONCORDBIO

OVERVALUED

Concord Biotech Limited

Pharma · NSE

↓ 74.2% vs fair value

52W Low

₹987

+3.9% from low

52W High

₹2,150

-52.3% from high

News sentiment (3 articles)

0 bull1 neutral2 bear

Valuation Gauge

OVERVALUED-74.2% Margin of Safety

OVERVALUEDFAIRLY VALUEDUNDERVALUED

Current Price

₹1,025

Fair Value

₹588

Fair Value Analysis

₹588

Based on free cash flow projections and earnings growth potential for Pharma sector companies | ROCE improving (latest 27.9%) — capital allocation becoming more efficient.

Medium confidence

Cash Flow Analysis

38% weight

₹188

Growth Valuation

63% weight

₹829

Price vs Market

CONCORDBIO

Nifty 50

Shareholding Pattern

Stock Health Score

Financially Strong

8.9 / 10

Profitability

10/10

ROE of 18.9% is above the Pharma sector benchmark of 18% — strong returns

Debt & Leverage

10/10

D/E ratio of 0.0x is well within the Pharma sector norm of 0.8x — strong balance sheet

Valuation vs Peers

8/10

P/E of 31.1x is slightly below the Pharma sector median of 42x — reasonably valued

Cash Flow

8/10

FCF margin of 11.3% — strong cash generation (₹133 Cr)

Earnings Growth

10/10

5yr EPS CAGR of 28.6% is well above the Pharma sector average of 15.3% — strong growth

Dividend

6/10

Dividend yield of 1.0% provides moderate shareholder returns

Sentiment Trend — Last 30 Days

Historical Returns

Key Ratios & Growth

FCF Yield

0.8%

Free cash flow / market cap

Revenue Growth (YoY)

+47.8%

Year-on-year revenue change

Profit Growth (YoY)

+66.9%

Year-on-year PAT change

Operating Cash Flow

₹245 Cr

TTM cash from operations

Key Financials

EPS (TTM)

₹32.9

P/E Ratio

31.1x

P/B Ratio

5.8x

ROE

18.9%

ROCE

26.8%

Debt / Equity

Beta

0.58

Div Yield

FCF (Cr)

₹133 Cr

Revenue (Cr)

₹1,180 Cr

EPS Growth 5Y

28.6%

Mkt Cap (Cr)

₹10,724 Cr

52W High

₹2,150.4

52W Low

₹987

Book Value/Share

₹175.9

Financial History

Period	Revenue	Op Profit	OPM%	PAT	EPS
TTM	₹1.2K Cr	₹437 Cr	38.0%	₹311 Cr	₹29.87
2025-03-31	₹1.2K Cr	₹506 Cr	42.0%	₹372 Cr	₹35.52
2024-03-31	₹1.0K Cr	₹432 Cr	42.0%	₹308 Cr	₹29.45
2023-03-31	₹853 Cr	₹344 Cr	40.0%	₹240 Cr	₹22.95
2022-03-31	₹713 Cr	₹270 Cr	38.0%	₹175 Cr	₹183.93
2021-03-31	₹616 Cr	₹327 Cr	53.0%	₹235 Cr	₹247.44
2020-03-31	₹512 Cr	₹205 Cr	40.0%	₹169 Cr	₹177.81

Compounded Growth Rates

Sales Growth

3Y+10.8%

5Y+13.5%

10Y—

Profit Growth

3Y+9.0%

5Y+5.8%

10Y—

EPS Growth

3Y+9.2%

5Y-34.5%

10Y—

Peer Comparison

Pharma

Stock	Price	Fair Value	MoS%	P/E	ROE	Signal
PAR Par Drugs And Chemicals Limited	₹86	₹469.7	+81.7%	7.3	15.4%	FAIRLY_VALUED
IOLCP IOL Chemicals and Pharmaceuticals Limited	₹79.5	₹237.8	+66.6%	19.6	5.2%	FAIRLY_VALUED
KILITCH Kilitch Drugs (India) Limited	₹132.7	₹321	+58.7%	17.7	9.4%	UNDERVALUED
BALPHARMA Bal Pharma Limited	₹69	₹147.5	+53.2%	12.8	12.6%	FAIRLY_VALUED
ZYDUSLIFE Zydus Lifesciences	₹868	₹1,502.2	+42.2%	17.6	19.9%	UNDERVALUED
NATCOPHARM Natco Pharma	₹1,030	₹1,597	+35.5%	11.8	18.0%	UNDERVALUED
JAGSNPHARM Jagsonpal Pharmaceuticals Limited	₹190.6	₹275.2	+30.7%	30.8	20.1%	UNDERVALUED
LUPIN Lupin	₹2,280	₹3,112	+26.7%	22.4	23.8%	UNDERVALUED